Direct ownership. Direct participation.
Qmona Ventures prepares each venture before external capital is committed. We secure the key rights, define ownership and governance, assemble the required partners and set the next milestone.
Selected investors participate directly in the new company alongside Qmona Ventures.
How it worksTurning breakthrough science into investable companies.
Identify the asset
We identify scientific and technological positions that can support a defensible company.
Form the venture
We secure the relevant rights, form the venture and define its ownership, governance and development plan.
Develop the company
We assemble the required scientific, technical and commercial capabilities and remain involved through the value-creating milestones.
Founder shares for investors.
When a new spin-off is formed, Qmona Ventures opens founding positions to selected family offices and entrepreneurial private investors. They subscribe at formation and receive founder shares — the share class the founding team itself holds.
Four questions before capital is committed.
Control
Can the core position be legally controlled and clearly allocated?
Milestone
Will the next milestone materially change the value of the asset?
Path
Is there a credible development, partnering and exit path?
Governance
Can downside, expenditure and stop decisions be governed?
The capabilities behind every venture.
From discovery to Phase I
Qmona Ventures is able to take a new chemical entity in the psychedelic-inspired category from drug discovery into its first clinical trial within twelve months — in Switzerland, where clinical research with psychedelic substances operates under a defined federal licensing regime, in continuous operation for over a decade.
From proof of concept to prototype
A dedicated in-house unit takes devices and advanced-materials concepts from first proof of concept to functional prototype — with the expertise, the people and the laboratories in place.
Built to learn
QAIOS — the Qmona Artificial Intelligence Operating System — is Qmona Ventures’ shared memory. It keeps track of the important choices we make and what happened as a result. Our experts make the decisions; QAIOS helps them use everything Qmona Ventures has already learned. Every company we build makes the next one stronger.
Ventures in development.
Neuropsychiatry
Psychedelic-inspired therapeutics, designed to scale psychedelic-assisted therapies.
Agricultural biologicals
Biological approaches intended to improve crop performance and reduce the use of water.
Watchmaking materials
Functional materials developed for demanding applications in fine watchmaking.
Next-generation oral nicotine
Development of differentiated nicotine formulations and product formats for adult consumers.
Art identification & provenance
Analytical methods supporting the authentication and provenance of artworks.
Instrument strings
Nanotechnology for premium, luthier-crafted string instruments — designed to unlock their full tonal potential.
Detailed information is made available selectively and, where appropriate, under NDA.
Selective by design.
Qmona Ventures is based in St. Gallen, Switzerland. The company builds a limited number of ventures at a time and works with family offices and entrepreneurial private investors. Specialist scientific, technical, legal and commercial partners are engaged as required.
Access begins with a conversation.
Qmona Ventures introduces selected private investors to science-based companies built with clear structure, clear ownership and a defined next step. Introductions are made in confidence.